Related Experiment Video
Updated: Apr 3, 2026
05:10
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
Published on: December 11, 2016
10.3K
Pharmacogenomics research: a potential strategy for drug development.
Die Pharmazie
|September 17, 2015
Summary
Pharmacogenomics (PGx) research links patient genetics to drug response, improving targeted therapies. However, translating PGx findings into drug development requires a comprehensive system and connected pipeline for wider clinical application.
Area of Science:
- Pharmacogenomics
- Genetics
- Drug Development
Background:
- Adverse drug reactions and ineffectiveness are common clinical issues.
- Patient genetic features significantly influence drug response.
- Pharmacogenomics (PGx) explores the relationship between genetics and drug efficacy.
Purpose of the Study:
- To highlight the role of pharmacogenomics in understanding drug response.
- To discuss the potential of in vitro and in vivo models in PGx research.
- To identify challenges and propose solutions for translating PGx into drug development.
Main Methods:
- Utilizing in vitro cell models and in vivo transgenic animal models to study genetic mutations' impact on drug response.
- Analyzing PGx-guided clinical trials for drug development benefits.
- Reviewing successes in targeted therapies driven by PGx drug targets.
Main Results:
- PGx research has led to successful targeted therapies (e.g., gefitinib, cetuximab).
- In vitro and in vivo models show potential for studying human genetic mutations and drug response.
- Despite progress, the translation of PGx into drug development remains unsatisfactory.
Conclusions:
- A comprehensive system involving stakeholders (individuals, medical staff, industry, government) is needed.
- A connected pipeline encompassing policy, research, genotyping, and clinical studies is crucial.
- Improving the translation of PGx into drug development requires a systematic, collaborative approach.
More Related Videos
06:40Author Spotlight: Cost-Effective Transcriptomic Drug Screening - Unlocking New Targets
Published on: February 23, 2024
1.9K
08:31Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
Published on: December 1, 2020
5.7K
Related Concept Videos
01:29Pharmacogenomics: Identification of New Drug Targets
86
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
86
01:29Pharmacogenetics and Pharmacogenomics: Overview
151
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
151
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
112
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
112
01:27Pharmacogenetics of Drug Metabolism: Overview
118
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
118
01:27Principles of Pharmacogenetics: Types of Genetic Variants
97
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
97
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
176
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
176